![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://i1.rgstatic.net/ii/profile.image/1061455319269378-1630082077848_Q128/Blaha-Larbaoui.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/publication/351409175/figure/tbl2/AS:1024793168064519@1621341139945/Treatment-emergent-Adverse-Events-Any-Grade-in-10-of-Total-Population-Related-to_Q320.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Türkiye Klinikleri Tıbbi Onkoloji - Özel Konular 2010 - Cilt 3 Sayı 3 | Dergiler | Türkiye Klinikleri Türkiye Klinikleri Tıbbi Onkoloji - Özel Konular 2010 - Cilt 3 Sayı 3 | Dergiler | Türkiye Klinikleri](https://www.turkiyeklinikleri.com/upload/issuecover/tibbionkolojiozel3-3-10kapak.jpg)
Türkiye Klinikleri Tıbbi Onkoloji - Özel Konular 2010 - Cilt 3 Sayı 3 | Dergiler | Türkiye Klinikleri
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/publication/349102191/figure/tbl2/AS:1022715091767297@1620845687644/Subgroup-analysis-of-subsequent-ICI-use-in-the-full-analysis-set_Q320.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC - The ASCO Post Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC - The ASCO Post](https://ascopost.com/media/14012157/18-ozguroglu.jpg)
Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC - The ASCO Post
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://i1.rgstatic.net/ii/profile.image/359041135071232-1462613485394_Q512/Mustafa-Oezgueroglu.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://i1.rgstatic.net/ii/profile.image/855551114244097-1580990689318_Q128/Ali-Goekyer.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Akciğer Kanseri. Tanı Tedavi Takip. Editörler. Antakya Konsensusu. Prof.Dr. Adnan Aydıner - Prof.Dr. Turhan Ece - Prof.Dr. - PDF Ücretsiz indirin Akciğer Kanseri. Tanı Tedavi Takip. Editörler. Antakya Konsensusu. Prof.Dr. Adnan Aydıner - Prof.Dr. Turhan Ece - Prof.Dr. - PDF Ücretsiz indirin](https://docplayer.biz.tr/docs-images/40/2006315/images/page_5.jpg)
Akciğer Kanseri. Tanı Tedavi Takip. Editörler. Antakya Konsensusu. Prof.Dr. Adnan Aydıner - Prof.Dr. Turhan Ece - Prof.Dr. - PDF Ücretsiz indirin
![PDF) Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: Report of first case PDF) Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: Report of first case](https://i1.rgstatic.net/publication/43343631_Primary_diffuse_large_B_cell_lymphoma_of_the_breast_eight_years_after_the_diagnosis_of_gastric_MALT_lymphoma_Report_of_first_case/links/0deec530200c58ec3f000000/largepreview.png)
PDF) Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: Report of first case
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/publication/349102191/figure/tbl3/AS:1022715091771393@1620845687675/OS-based-on-the-primary-analysis-naive-sensitivity-analysis-and-IPCW-model_Q320.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/dd6c5bd6-1cde-4ec9-b5a2-f0223bd5183c/gr1_lrg.jpg)